Does RAMIPRIL Cause Second primary malignancy? 22 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Second primary malignancy have been filed in association with RAMIPRIL (Ramipril). This represents 0.1% of all adverse event reports for RAMIPRIL.
22
Reports of Second primary malignancy with RAMIPRIL
0.1%
of all RAMIPRIL reports
3
Deaths
19
Hospitalizations
How Dangerous Is Second primary malignancy From RAMIPRIL?
Of the 22 reports, 3 (13.6%) resulted in death, 19 (86.4%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RAMIPRIL. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does RAMIPRIL Cause?
Acute kidney injury (3,286)
Dyspnoea (2,537)
Dizziness (2,490)
Hypotension (2,417)
Fatigue (2,415)
Drug ineffective (2,412)
Nausea (2,219)
Vomiting (2,055)
Off label use (2,053)
Hypertension (2,046)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which RAMIPRIL Alternatives Have Lower Second primary malignancy Risk?
RAMIPRIL vs RAMUCIRUMAB
RAMIPRIL vs RANEXA
RAMIPRIL vs RANIBIZUMAB
RAMIPRIL vs RANIMUSTINE
RAMIPRIL vs RANITIDINE